{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-011613","form_type":"8-K","ticker":"FEMY","cik":"0001339005","company_name":"FEMASYS INC","filed_at":"2024-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.869084+00:00","generated_at":"2026-06-05T02:26:59.972908+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Femasys completes first in-office commercial FemaSeed infertility procedure","bullets":["First commercial procedure using FDA-cleared FemaSeed intratubal insemination performed in Saginaw, Michigan.","CEO cites FemaSeed as cost-effective, safer alternative to IVF amid Alabama Supreme Court frozen embryo ruling.","Top-line pivotal data from FemaSeed study expected to be announced in Q1 2024.","Procedure conducted by Dr. Andrew Wagner of Women's OB-GYN PC."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-011613","json":"https://secwatch.observer/filing/0001140361-24-011613.json","markdown":"https://secwatch.observer/filing/0001140361-24-011613.md","text":"https://secwatch.observer/filing/0001140361-24-011613.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339005/000114036124011613/0001140361-24-011613-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339005/000114036124011613/ef20023361_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T02:26:59.972908+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}